Acute Liver Failure (ALF)– Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Acute liver failure (ALF) is a rare
and frequently heterogeneous presentation of severe liver dysfunction in a
patient with no prior history of liver disease. Despite its high morbidity and
mortality, survival has improved due to advances in intensive care management
and emergency liver transplantation. Hepatitis A and E are the leading causes
of liver failure, with most cases occurring in developing countries.
Drug-induced hepatitis accounts for nearly half of all ALF cases in the United
States, with acetaminophen being the most common cause. Hepatitis B infection
may result in liver failure due to both acute conditions and reactivation of
hepatitis B following the start of immunosuppressive therapy. Co-infection with
hepatitis B and C may result in ALF, though this is uncommon with hepatitis C
alone. Herpes simplex virus, Epstein-Barr virus (EBV), Parvoviruses,
cytomegalovirus (CMV), adenovirus, and varicella-zoster virus are all viral
etiologies of ALF.
·
The incidence of Acute Liver Failure (ALF)
ranges from 0.85 to 1.1 cases per 100,000 population in the USA.
Thelansis’s “Acute Liver Failure (ALF)
Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Acute
Liver Failure (ALF) treatment modalities options for eight major markets (USA,
Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Acute Liver Failure (ALF) across 8 MM market from the centre of Excellence/
Public/ Private hospitals participated in the study. Insights around current
treatment landscape, epidemiology, clinical characteristics, future treatment
paradigm, and Unmet needs.
Acute Liver Failure (ALF) Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment